Exact Sciences : ESG Report for the FY ended 12/31/2023

WE'RE HELPING ERADICATE CANCER BY PREVENTING IT, DETECTING IT EARLIER, AND GUIDING PERSONALIZED TREATMENT.

2023 ESG REPORT

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

TABLE OF CONTENTS

3	Reporting our progress	21	Wellness programs	48	Product quality
4	Letter from Chairman and CEO	22	Satisfaction & engagement	51	Corrective & preventive action
5	2023 highlights	25	Recognizing team members	53	Access to health care
6	Flagship tests	26	Career development	54	Access to tests
7	Financial performance	28	Learning & development	55	Health equity initiatives
8	Advancing our pipeline	29	Diversity, equity & inclusion	57	Environmental stewardship
9	Taking care of the people we serve	30	Occupational health & safety	58	Greenhouse gas emissions
10	Improving quality of life with Cologuard®	32	Community engagement	58	Water management
11	Power of early detection	33	Community partnerships	59	Energy management
12	Leigh Anne's story	37	Business ethics	59	Waste management
13	About the Oncotype DX Breast Recurrence Score®	38	Compliance programs	60	Employee-led sustainability
14	Ayako's story	39	Integrity Alertline	61	Appendix
15	COVID-19 response	39	Cybersecurity & data protection	62	Sustainability Accounting Standards
16	Materiality	40	Human & labor rights		Board (SASB) Index
17	Key sustainability focus areas	41	Supplier management	66	Task Force on Climate-Related Financial
18	Human capital	42	Board oversight		Disclosures (TCFD) Index
19	Talent attraction & onboarding	43	Addressing shareholder feedback
20	Compensation & benefits	44	Clinical research

2

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

REPORTING OUR PROGRESS

Our 2023 ESG report seeks to provide decision-useful sustainability information to our stakeholders. This report covers 2023 information for our global operations, unless stated otherwise. The content has been informed by leading ESG and sustainability reporting frameworks such as the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-Related Financial Disclosures (TCFD). We strongly support these frameworks and align with their disclosure recommendations, which are provided in the appendix.

All data included in this report has been reviewed by our internal accounting team but has not been externally verified.

3

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

LETTER FROM OUR CHAIRMAN & CEO

At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.

We serve health systems, health care providers, and patients with the best tests, including Cologuard® and Oncotype DX®. Our work makes a lasting impact on our people, our communities, and the planet.

Our 2023 Environmental, Social, and Governance Report (ESG) features several employee-driven sustainability efforts. Our team shows a collective dedication to doing the right thing the right way. We build sustainable and responsible practices into all we do to advance our purpose.

This report outlines our progress in key focus areas, including:

• Human capital
• Community engagement
• Business ethics
• Product quality
• Access to health care
• Environmental stewardship

During 2023, we tested a record 4.1 million patients for cancer and rare diseases. We also became profitable, achieving $219 million in adjusted EBITDA while growing core revenue by 24% to $2.5 billion. With these results, we are ready to magnify our impact in the global fight against cancer.

We achieved these results thanks to the dedication of our world-class team. Exact Sciences' purpose-driven culture helps us attract and retain the best people. They want to work for a company that makes a profound difference in cancer care and in the world at large. We are proud of how they deliver on that every day.

Kevin Conroy

Chairman and Chief Executive Officer

4

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

EXACT SCIENCES AT A GLANCE IN 2023

6,500 4M+

40+ locations globally in 20 cities

employees dedicated	tests delivered
to defeating cancer

Great Place To Work®

certified for the fifth consecutive year

45%

of total waste recycled

53%

120

countries where we supported patients

400K+

global network of ordering providers

12,000+

workforce gender diversity	hours of volunteer service	5

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

OUR FLAGSHIP TESTS

SCREENING

Cologuard® is the first and only FDA-approved,non-invasive,multi-target,stool-based colorectal cancer screening test. There are nearly 110 million Americans at average risk for colorectal cancer who should be screened regularly. Today, an estimated 60 million of them are not up to date with screening recommendations. The Cologuard test has helped screen more than 14 million people since it was made available in 2014 and has captured about 10% of the addressable market. Our long- term goal is to help meaningfully increase colorectal cancer screening rates and eradicate this terrible disease by capturing 40% of the market with Cologuard, which equates to about

$7 billion in revenue.

PRECISION ONCOLOGY

The Oncotype DX Breast Recurrence Score® is the only test that can predict, with precision, the individual benefit of chemotherapy and risk of recurrence for early-stage breast cancer patients, as published in the landmark TAILORxand RxPONDERtrials. The Oncotype DX test is internationally recognized as standard of care for patients with early- stage, HR-positive,HER2-negative breast cancer.

The OncoExTra® test gives doctors and their late-stage cancer patients a complete molecular picture of the patient's cancer to help inform treatment options. It is a comprehensive DNA- and RNA-based genomic test that provides reliable and actionable results personalized to each patient. The OncoExTra test works by profiling the entire exome (DNA) and transcriptome (RNA) across approximately 20,000 genes.

6

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

FINANCIAL PERFORMANCE

$2.50B

2023 revenue, 24% core growth Y/Y

70%+

2023 gross margins

$470M

Y/Y free cash flow improvement

Exact Sciences generated a record $2.5 billion in revenue in 2023, an increase of 20%, or 24% on a core revenue basis, with Screening revenue of $1.86 billion and Precision Oncology revenue of $629 million. Strong revenue growth and industry-leading gross margins powered $219 million in positive adjusted EBITDA for the year ended December 31, 2023.

30%+ revenue CAGR

Adj. EBITDA improved $362M Y/Y

Please refer to the appendix for reconciliations to GAAP financial measures.

7

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

ADVANCING OUR PIPELINE OF LIFE-CHANGING TESTS

Colorectal cancer	Multi-cancer	Molecular residual disease and
screening (CRC)	screening	recurrence monitoring (MRD)
110M	135M	12M
people eligible for	potential people eligible	annual U.S. testing
screening in U.S.	for screening in U.S.	opportunities

We are working to solve the biggest problems in cancer care. Our advanced research and development expertise and platform spanning the cancer continuum will help bring the next wave of life-changing tests to more patients. We made meaningful progress in each of our key pipeline programs in 2023 by:

• Announcing positive results from the pivotal BLUE-C study, in which our next-generation Cologuard® test exceeded our expectations for improved sensitivity and specificity
• Making meaningful progress on our molecular residual disease test development in colon cancer and breast cancer
• Advancing our multi-cancer screening test development and initiating a collaboration with Baylor Scott & White to generate real-world evidence

Source: U.S. Census data, Exact Sciences estimates; includes U.S. markets only

8

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

TAKING

CARE OF THE PEOPLE WE SERVE

We are helping to change the way cancer is detected and treated. From screening to treatment guidance, we deliver the clarity that people need to make more informed cancer care decisions.

9

TABLE OF CONTENTS

2023ESG REPORT

HUMAN CAPITAL

COMMUNITY ENGAGEMENT

BUSINESS ETHICS

PRODUCT QUALITY

ACCESS TO HEALTH CARE

ENVIRONMENTAL STEWARDSHIP

IMPROVING QUALITY OF LIFE WITH

For every 1 million patients	By the end of 2023,
screened with Cologuard,	we delivered
318K	14M+
years of life are gained	Cologuard test results

Heath economics models show that Cologuard can lead to

65% reduction in colorectal cancer incidence

73% reduction in colorectal cancer mortality

Source: Imperiale TF et al., N Engl J Med (2014); Gagrat ZD et al., ASCO GI Cancers Symposium (2022); numbers presented here based on modeling analysis performed on Jan. 13, 2022 using point estimates of performance,
CRCAIM Natural History version 1.0.5, and CRC-AIM Screening version 1.0.9; simulated a population of 2M individuals screened between ages 45 & 75 with mt-sDNA 1.0 every 3 years - reported results per 1M screened	10